ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug-Induced Liver Injury Network Experience.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Response to Letter to the Editor.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Common Causes of Drug-Induced Liver Injury in 2025.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
backgroundWe aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD).
methodsUsing the Drug-Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non-IBD indications (but excluding corticosteroids). HLA allele associations were investigated.
resultsAmong 1806 participants, 81 (4.5%) had IBD-agent DILI: 31 biologics (27 infliximab), 35 immunomodulators (31 azathioprine/mercaptopurine), 14 aminosalicylates (11 sulfasalazine) and 1 small molecule (tofacitinib). Median age was 45 years with 75% female and 78% White. Patients with biologic-DILI were younger, had longer latency (median 124 days), predominantly hepatocellular injury (78%) and mostly mild severity (74%) with no deaths and one chronic case. Immunomodulator-DILI was mainly cholestatic or mixed, with jaundice in 57%; two were fatal, one required transplant and five became chronic. Aminosalicylate-DILI had the shortest latency (median 40 days), was hepatocellular (57%) or cholestatic (36%), often with rash (50%) or pruritus (36%), mostly mild (64%), with two chronic cases. DILI phenotype was similar with IBD and non-IBD indications. Multiple HLA alleles were associated with infliximab (HLA-DPB1*01:01, HLA-B*08:01 and HLA-DQB1*02:01) azathioprine (HLA-DR3, HLA-DRB1*03:01 and HLA-A*33:01), mercaptopurine (HLA-A*11:01 and HLA-B*37:01) and sulfasalazine (HLA-B*53:01) DILI, compared to population controls and other DILI cases.
conclusionsClinical features such as latency, injury pattern, jaundice and dermatologic findings help distinguish implicated agents and guide prognosis in suspected DILI from IBD therapies. HLA alleles may help identify individuals at higher DILI risk and support causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.